SCHEMBL16933568

SCHEMBL16933568

CNC(=O)c1ccc(-c2ccc(C(C)(C)N(C(=O)O)C3CCN4CCC3CC4)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPY2R P49146 1/20 0.38
▸ EPHX2 P34913 1/20 0.36
▸ NR1H4 Q96RI1 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ MCHR1 Q99705 2/20 0.35
▸ GPR119 Q8TDV5 2/20 0.35
▸ KDR P35968 1/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ DGAT1 O75907 1/20 0.35
▸ CHRNA7 P36544 2/20 0.35
▸ SCD O00767 1/20 0.34
▸ SCD5 Q86SK9 1/20 0.34
▸ MKNK1 Q9BUB5 1/20 0.34
▸ MKNK2 Q9HBH9 1/20 0.34
▸ HTR3E A5X5Y0 1/20 0.34
▸ HTR3B O95264 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ HTR3A P46098 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16933536 0.92 CHRNA7 (0.38) NPY2REPHX2NR1H4MCHR1CHRNA7
SCHEMBL16933425 0.79 RORC (0.35) KCNH2
SCHEMBL16933470 0.76 CHRM5 (0.39) GPR119
SCHEMBL16933539 0.76 DRD2 (0.36) CHRNA7
SCHEMBL16933565 0.75 GPR119 (0.39) NPY2RGPR119KCNH2USP30
SCHEMBL16933987 0.74 FLT3 (0.36) GPR119
SCHEMBL16933520 0.74 PRKAB2 (0.38) ALDH1A1GPR119KCNH2
SCHEMBL16933664 0.74 CHRM5 (0.41) —
SCHEMBL16933615 0.73 MAPT (0.42) ALDH1A1SMN1; SMN2GPR119
SCHEMBL16933446 0.73 CHRNA7 (0.41) CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4098654-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS Genzyme Corporation (US) 2022-12-07 — — EP disclosed
EP-2895484-B1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORP (US) 2022-02-23 — — EP disclosed
US-20150210681-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2015-07-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210681-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA NPY2R 4366/4885EPHX2 1284/4885NR1H4 2275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback